Intravesical MMC has been a standard of care for the treatment of bladder cancer for over 30 years. As an extension of that use, physicians at various centers have also administered it intravesically ...

There is limited evidence to support the use of adjuvant chemotherapy (AC) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Against this backdrop, we hypothesized ...

Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy, according to data presented at ...

To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper ...

Please provide your email address to receive an email when new articles are posted on . New 5-year DFS further supports adjuvant chemotherapy after nephroureterectomy for treatment of this patient ...

Patients with high grade and/or muscle invasive bladder cancer and with concomitant diseases of the upper urinary tract, e.g. urothelial tumors (transitional cell carcinoma - TCC) or afunctional ...

Owing to the development of the laparoendoscopic single-site (LESS) procedure, transumbilical LESS nephroureterectomy (LESS-NU) has become a new approach for treating upper tract urothelial carcinoma.

In a study, distant metastasis emerged as the best candidate to be a surrogate end point for survival among patients receiving surgical treatment for UTUC. Progression to distant metastasis within 3 ...

"Patients with decreased eGFR at baseline are often those we are most interested in preserving their renal function with NSS. However, it was this cohort in whom we did not see any renal function ...

Background: Urothelial carcinoma (UC) is a common cancer affecting many patients in the United States. Nephroureterectomy remains the gold standard for the treatment of high grade upper tract disease ...